Dr. Tareq Abadl: What If Blood Matching Went Deeper than Just ABO and Rh?
Dr. Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, shared a post on LinkedIn:
“Precision Transfusion Medicine
What if blood matching went deeper than just ABO and Rh?
Molecular blood-group genotyping analyzes a patient’s blood-group genes to predict dozens of clinically significant antigens — transforming modern transfusion practice.
1. Deeper and Safer Matching
Genotyping identifies variant and weak alleles that routine serology may miss, such as:
Weak/Partial D variants
Rh, Kell, Kidd, Duffy, and MNS variants
This reduces the risk of alloimmunization, especially in patients requiring chronic transfusions (e.g., sickle cell disease, thalassemia).
2. Faster Compatible Unit Selection
Creating a genotyped donor registry allows rapid identification of best-matched units, which is crucial for patients with:
Multiple alloantibodies
Rare or complex phenotypes
3. Improved Antenatal Care
Molecular typing enhances:
Prediction of fetal antigen status
Early assessment of hemolytic disease of the fetus and newborn (HDFN)
Guidance on monitoring and intervention
4. Practical Limitations
Genotyping is powerful but works alongside serology, not as a replacement:
It predicts antigen expression, which may not always equal phenotype
Results can be affected after allogeneic stem-cell transplant or recent transfusion
Use buccal swabs or pre-transfusion samples when needed
Requires proper quality control and expert interpretation
5. Better Donor Strategy and Inventory
Molecular typing helps:
Recruit and flag rare-donor phenotypes
Improve blood-bank inventory management
Provide safer, more reliable matching for high-risk patients
How You Can Act
For Transfusion Professionals:
Implement targeted genotyping for chronically transfused or alloimmunized patients.
For Blood Donors:
Join local rare-donor programs if available — you may save lives in ways only a few can.
Find more posts featuring Dr. Tareq Abadl on Hemostasis Today.
-
May 12, 2026, 11:13Matteo Foschi: Grateful To Be Selected for The WSO Future Stroke Leaders Programme
-
May 12, 2026, 11:05Omid Seidizadeh: Strategies to Guide The 2nd 100 years of VWD Care and Research
-
May 12, 2026, 11:01Kate Scrivener: The Big Picture of Exercise Trials to Prevent Falls After Stroke
-
May 12, 2026, 10:39Rucha Patil: Our ”Factor VIII Inhibitor Point-of-Care Diagnostic” Is Successfully Transferred at Science-Tech
-
May 12, 2026, 10:26Fabrice Cognasse: The EFS Is First and Foremost Part of a Medical Discipline – Transfusion
-
May 11, 2026, 16:52Luke McLaughlin: Raising Awareness on Haemophilia Issues at ENIL Lead On
-
May 11, 2026, 16:49Jeff Sternlicht: Normal LDL Does Not Always Mean Low Risk
-
May 11, 2026, 16:42Archil Jaliashvili: From Managing Blood to Managing Oxygen Metabolism
-
May 11, 2026, 16:42Heghine Khachatryan: Celebrating One Hundred Years of von Willebrand Disease with EHC